Abstract
During the past two years, clinical studies have attempted to identify risk factors to predict clinical outcomes following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In July 2021, a study using a high-throughput technique detected autoantibodies to chemokines, cytokines, and complement components in patients with symptomatic coronavirus disease 2019 (COVID-19). In August 2021, a study identified pre-existing autoantibodies to type 1 interferons (IFNs) in 10% of patients with severe COVID-19 but not asymptomatic individuals. Autoantibodies may be the long-awaited markers of clinical risk for severe COVID-19 in patients with SARS-CoV-2 infection. This Editorial aims to present some recent findings of autoantibodies to components of the immune system, including type 1 IFNs, and the risk of severe COVID-19.
【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, coronavirus, Risk factors, Cytokines, severe COVID-19, SARS-COV-2 infection, Infection, interferons, risk, complement, chemokines, immune system, risk factor, severe acute respiratory syndrome Coronavirus, clinical outcomes, Clinical outcome, Asymptomatic individuals, autoantibodies, symptomatic, Patient, Clinical studies, respiratory, predict, IFNs, marker, clinical study, autoantibody, complement components, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, components, type 1 interferons, component, clinical risk, editorial, type 1 interferon, identify, recent finding, patients with SARS-CoV-2, 【제목키워드】 COVID-19, component, System, Including,